January 31, 2017
Sunovion Pharmaceuticals, a US subsidiary of Sumitomo Dainippon Pharma, said that the US FDA approved its atypical antipsychotic drug Latuda (lurasidone) for an additional indication of schizophrenia in adolescents aged 13 to 17 years. A supplemental new drug application for...read more